Ex-partners are attempting to learn if their equity in firm will be worth anything
Related stories
An overlooked energy source could solve AI’s power crunch — and these 2 stocks are prime plays
Medicare prescription drug costs will jump 50% in 2027. Doing nothing could cost you.
America’s renters are in serious trouble
Trump faces midterm reckoning in Pennsylvania’s ‘swingiest’ district
Once election results are in, here’s what investors should focus on next
Billionaire Mark Walter has explored sale of $71bn insurer Delaware Life